Custom Manufacturing, Project Outsourcing, your Trusted Partner from China
Acute Myeloid Leukemia (AML) presents a complex clinical picture, where overcoming the initial diagnosis and achieving remission is often just the first step. The challenge of preventing relapse remains a significant concern for patients and clinicians, especially for those with intermediate-to-low-risk disease. NINGBO INNO PHARMCHEM CO.,LTD. is a supplier of critical pharmaceutical intermediates used in the development of advanced AML therapies, including those focused on maintenance.
The fight against AML relapse is being significantly influenced by the advent of targeted therapies and combination treatments. Specifically, the use of Venetoclax (VEN) in conjunction with Azacitidine (AZA) has shown remarkable efficacy. Research indicates that for patients with intermediate risk AML, employing VEN-AZA maintenance therapy can dramatically reduce the likelihood of the disease returning. This has a direct impact on progression-free survival (PFS), offering patients a greater chance at sustained remission.
For patients with low risk AML, the exploration of maintenance therapy is equally crucial. The goal is to build upon the initial success of treatment and prevent the disease from re-establishing itself. This proactive approach, enabled by compounds synthesized from high-quality intermediates supplied by NINGBO INNO PHARMCHEM CO.,LTD., aims to improve overall survival rates.
The understanding of venetoclax azacitidine adverse events is also a key part of the treatment paradigm. While treatments aim for maximum efficacy, minimizing toxicity is equally important. The development of these therapies relies on precise synthesis, where the quality of pharmaceutical intermediates plays a vital role in the final drug product's safety and effectiveness. Reports often detail common side effects, and ongoing research seeks to optimize dosing and management protocols.
Furthermore, the achievement of MRD negative status is increasingly recognized as a critical indicator of successful treatment and a predictor of long-term outcomes in AML. The strategies involving VEN-AZA aim to induce and maintain this deeper level of remission, offering patients a more durable and hopeful prognosis. NINGBO INNO PHARMCHEM CO.,LTD. is proud to support these vital advancements in cancer treatment by providing reliable and high-quality pharmaceutical intermediates.
Manufacturing Facilities
Professional Export Experience
to Global Customers
1. 20 years of R&D, manufacturing and sales experience, serving customers in 60 countries and regions around the world;
2. Own R&D laboratory, pilot platform and large-scale production workshop, which can meet the audit requirements of global customers;
3. We can satisfy customers' perfect transition from small scale lab requirements (gram level) to commercialization requirements (hundred tons level).
A: We don't have Minimum Order Quantity, exact quantity should be provided before quotation for us to calculate the exact cost.
A: We don't provide free samples due to lots of request and expensive international courier's cost, we can deduct the sample charge after commercial order placed.
A: Our payment terms: Small or sample order: T/T IN ADVANCE. Commercial order: First order should be by T/T IN ADVANCE or L/C at sight, and following orders T/T 30~90days is acceptable subject to approval of credit application.
